




Canada's National Laboratory for Particle  
and Nuclear Physics


# Medical isotope production at TRIUMF - from imaging to treatment

Cornelia Hoehr  
Research Scientist, Life Sciences






- PET isotopes
- SPECT isotope
- $\alpha$  emitters





Routine production of  $^{11}\text{C}$  and  $^{18}\text{F}$


$^{68}\text{Ga}$ ,  $^{89}\text{Zr}$ ,  $^{44}\text{Sc}$ ,  $^{86}\text{Y}$   
 $^{11}\text{C}$ ,  $^{18}\text{F}$ ,  $^{13}\text{N}$ ,  $^{94\text{m}}\text{Tc}$ ,  
 $^{61/64}\text{Cu}$ ,  $^{52}\text{Mn}$ ,  $^{55}\text{Co}$ ,  
 $^{117/118/119}\text{Sb}$ ,  
 $^{192}\text{Ir}$



Routine production of  $^{11}\text{C}$  and  $^{18}\text{F}$










- Decentralized Production
  - $^{99m}\text{Tc}$  locally produced, locally used, competitively priced
  - Redundant supply to avoid widespread shortages
  - Complementary to:
    - other medical isotopes produced by cyclotrons ( $^{18}\text{F}$ )
    - other sources of  $^{99m}\text{Tc}$







- Hundreds of co-produced isotopes including;
- $^{225}\text{Ra}$ ,  $^{225}\text{Ac}$ ,  $^{224}\text{Ra}$ ,  $^{223}\text{Ra}$ ,  $^{213}\text{Bi}$ ,  $^{212}\text{Pb}$ ,  $^{212}\text{Bi}$ ,  $^{209/211}\text{At}$



## Isotope production using TRIUMF's 500 MeV infrastructure

### 1) ISAC – ISOL (Research, Feasibility)

Low activity (kBq to MBq), high purity

### 2) 500 MeV – IPF (BL1A)


Intermediate activity (MBq), spallation

- Routine, independent production


### 3) ARIEL/H<sup>+</sup>

High activity (GBq), spallation

- Enable radiopharmaceutical development and clinical trials





Experiments underway







rod diameters [mm]

High Energy Collimator



High Sensitivity Collimator





## Isotope production using TRIUMF's 500 MeV infrastructure

### 1) ISAC - ISOL

Low activity (kBq to MBq), high purity

- Feasibility chemistry, radiolabeling

### 2) 500 MeV – IPF (BL1A)


Intermediate activity (MBq), spallation

- Routine, independent production

### 3) ARIEL/H<sup>+</sup>

High activity (GBq), spallation

- Enable radiopharmaceutical development and clinical trials



500 MeV Isotope Production Facility

- Extraction of  $^{225}\text{Ac}$  product from Th metal has been demonstrated


Chemical yield: > 85%

- Directly produced Ac fraction contains toxic  $^{227}\text{Ac}$  ( $t_{1/2} = 22 \text{ y}$ )

$$^{227}\text{Ac}/^{225}\text{Ac} = 0.1 - 0.2\%$$

- Isolation of  $^{225}\text{Ac}$  from Ra fraction could reduce  $^{227}\text{Ac}$  impurities

V Radchenko et al. J. Chromatog. A., 2015, 1380, 55



Aliev et al., Solvent Extraction and Ion Exchange (32), 2014.

Process steps:


- 1) Th Irradiation
- 2) Ra/Ac separation 1 week EOB – gives primary Ac fraction
- 3) Recovered Ra allowed to sit for 17.5 days
- 4) Ra/Ac separation – gives secondary Ac fraction

First run with Th oxide 2016

First run with Th Dec 2017

Primary Ac Fraction			
days from Ra/Ac isolation	0	1	5
<b>Ac-225 [MBq]</b>	<b>42.2</b>	<b>39.4</b>	<b>29.9</b>
Ac-228/Ac-225 [%]	0.039	0.003	0.000
Ac-227/Ac-225 [%]	0.185	0.198	0.261
Ac-226/Ac-225 [%]	16.020	9.740	1.330

Secondary Ac Fraction		
days from Ra/Ac isolation	0	2
<b>Ac-225 [MBq]</b>	<b>2.2</b>	<b>1.9</b>
Ac-228/Ac-225 [%]	0.882	0.003
Ac-227/Ac-225 [%]	9.951E-09	9.949E-09
Ac-226/Ac-225 [%]	0.000	0.000





## Isotope production using TRIUMF's 500 MeV infrastructure

### 1) ISAC - ISOL

Low activity (kBq to MBq), high purity

- Actinide targets
- Feasibility chemistry, radiolabeling

### 2) 500 MeV – IPF (BL1A)


Intermediate activity (MBq), spallation

- Routine, independent production



### 3) ARIEL/H<sup>+</sup>

High activity (GBq), spallation

- Enable radiopharmaceutical development and clinical trials



- 400 mCi (15 GBq)  $^{225}\text{Ac}$  per target (FLUKA; A. Gottberg)
- Irradiation schedule decoupled from science target
- ARIEL Proton Station commissioning scheduled for 2021
- \$9.8M for infrastructure




$^{225}\text{Ra}/^{225}\text{Ac}, \dots$

$^{209}/^{211}\text{At},$   
 $^{225}\text{Ra}/^{225}\text{Ac}$

$^{99\text{m}}\text{Tc}$

TR30  
cyclotron

$^{68}\text{Ga}, ^{89}\text{Zr}, ^{44}\text{Sc}, ^{86}\text{Y}$   
 $^{11}\text{C}, ^{18}\text{F}, ^{13}\text{N}, ^{94\text{m}}\text{Tc},$   
 $^{61}/^{64}\text{Cu}, ^{52}\text{Mn}, ^{55}\text{Co},$   
 $^{117}/^{118}/^{119}\text{Sb},$   
 $^{192}\text{Ir}$





Canada's national laboratory for  
particle and nuclear physics

Laboratoire national canadien  
pour la recherche en physique  
nucléaire et en physique des  
particules

TRIUMF: Alberta | British Columbia | Calgary |  
Carleton | Guelph | McGill | Manitoba | McMaster |  
Montréal | Northern British Columbia | Queen's |  
Regina | Saint Mary's | Simon Fraser | Toronto |  
Victoria | Western | Winnipeg | York

Thank you!  
Merci!

Follow us at TRIUMFLab

